Hemophilia Market To Reach $20.45 Billion by 2035

Hemophilia market was valued at $13.11 billion in 2025 and is projected to reach $20.45 billion by 2035, growing at a CAGR of 4.5% during the forecast period (2026–2035). The increasing prevalence of rare bleeding disorders is a key macro driver supporting market growth. According to the World Health Organization, hemophilia affects approximately 1 in 10,000 people globally, with thousands of new cases diagnosed each year. The rising awareness and improved diagnostic capabilities are leading to higher detection rates, particularly in developing regions. Additionally, increasing government initiatives and funding programs for rare diseases are enhancing treatment accessibility, thereby driving demand for hemophilia therapeutics worldwide.

Browse the full report description of “Hemophilia Market Size, Share & Trends Analysis Report, By Product Type (Clotting Factor Replacement Therapy, Extended Half-Life (EHL) Factor Products, Non-Factor Replacement Therapy, Gene Therapy), By Technology Platform (Recombinant DNA Technology, Plasma Fractionation Technology, Fc Fusion / PEGylation, RNA Interference (RNAi), Gene Transfer (AAV Vectors)), By End User (Hospitals & Hemophilia Treatment Centers (HTCs), Specialty Clinics, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/hemophilia-market

The expansion of advanced biopharmaceutical technologies is further strengthening the market outlook. According to the U.S. Food and Drug Administration, there has been a steady rise in approvals for biologics and gene therapies targeting rare diseases, including hemophilia. Furthermore, the European Federation of Pharmaceutical Industries and Associations highlights significant investments in plasma-derived and recombinant therapies, supporting innovation in treatment approaches. Hospitals and hemophilia treatment centers (HTCs) remain the dominant end users due to access to specialized care, while homecare settings are gaining traction with the increasing adoption of self-administration therapies and patient-centric treatment models.

Rising Adoption of Gene Therapy and Non-Factor Treatments Driving Market Growth

The technology segment is witnessing strong growth due to the increasing adoption of gene therapy and RNA interference-based treatments. Clotting factor replacement therapy continues to dominate due to its established efficacy, while extended half-life (EHL) factor products are gaining momentum owing to reduced dosing frequency. Non-factor replacement therapies are emerging as a transformative segment due to improved safety profiles and ease of administration. Gene therapy is expected to be the fastest-growing segment, as it offers the potential for long-term or curative outcomes, significantly reducing treatment burden. The end-user landscape is evolving with hospitals maintaining dominance, while specialty clinics and homecare settings are expanding rapidly due to advancements in remote care and self-infusion technologies.

Key Leaders Transforming the Hemophilia Market

The key players in the hemophilia market include Genentech, Takeda Pharmaceuticals, Novo Nordisk, Sanofi, CSL Behring, among others. These companies are focusing on product innovation, strategic collaborations, and expansion strategies to strengthen their market presence.

• In March 2026, Takeda Pharmaceutical Company announced the next phase of its global transformation strategy aimed at strengthening competitiveness and accelerating long-term growth. The initiative focuses on streamlining corporate functions, leveraging advanced technologies, and bringing operations closer to patients and customers. The company expects to generate annual cost savings exceeding JPY 200 billion by 2028, which will be reinvested into late-stage pipeline development and upcoming product launches, including oveporexton, rusfertide, and zasocitinib, enhancing its innovation and market positioning.
• In March 2025, Sanofi received approval from the U.S. Food and Drug Administration for Qfitlia (fitusiran), the first antithrombin-lowering therapy for routine prophylaxis in hemophilia A or B patients with or without inhibitors. The therapy, based on RNA interference technology, demonstrated significant reduction in annualized bleeding rates in Phase 3 ATLAS studies and requires as few as six injections per year, offering improved patient convenience and treatment adherence while strengthening Sanofi’s position in next-generation hemophilia therapeutics.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Technology Platform
• End User
• Competitive Landscape – Genentech, Takeda Pharmaceuticals, Novo Nordisk, Sanofi, CSL Behring, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Hemophilia Market Segmentation

By Product Type

• Clotting Factor Replacement Therapy
• Extended Half-Life (EHL) Factor Products
• Non-Factor Replacement Therapy
• Gene Therapy

By Technology Platform

• Recombinant DNA Technology
• Plasma Fractionation Technology
• Fc Fusion / PEGylation (Half-life extension)
• RNA Interference (RNAi)
• Gene Transfer (AAV Vectors)

By End User

• Hospitals & Hemophilia Treatment Centers (HTCs)
• Specialty Clinics
• Homecare Settings

Global Hemophilia Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hemophilia-market